Atea Pharmaceuticals downgraded by SVB Leerink
$AVIR
Biotechnology: Pharmaceutical Preparations
Health Care
SVB Leerink downgraded Atea Pharmaceuticals from Outperform to Mkt Perform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/13/2024 | $2.00 → $6.88 | Underweight → Equal-Weight | Morgan Stanley |
| 8/10/2023 | Neutral → Underweight | JP Morgan | |
| 3/2/2022 | $10.00 → $8.00 | Neutral | JP Morgan |
| 3/1/2022 | $10.00 → $9.00 | Market Perform | SVB Leerink |
| 2/16/2022 | $11.00 → $10.00 | Market Perform | SVB Leerink |
| 1/6/2022 | $14.00 → $7.00 | Equal-Weight → Underweight | Morgan Stanley |
| 11/18/2021 | Outperform → Mkt Perform | SVB Leerink | |
| 11/18/2021 | $11.00 | Outperform → Market Perform | SVB Leerink |
Global Phase 3 HCV Program Expected to Initiate in 1Q 2025 Potential Best-in-Class Profile of Bemnifosbuvir + Ruzasvir Regimen Supports Opportunity to Disrupt and Expand Global HCV Market of Approximately $3 Billion in Annual Net Sales The Regimen, if Approved, Should Play an Important Role in Efforts to Reduce the Continuing High Disease Burden of HCV BOSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, will outline the Company's strategic priorities for 2025 at the 43rd Annual J.P. Morgan Health
BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, will present a business update at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 5:15 p.m. PT in San Francisco, CA. A live webcast of the presentation will be available here and on the Company's website at https://ir.ateapharma.com. An archived webcast will be available on Atea Pharmaceuticals' website for at least 90 days foll
Bradley L. Radoff and Michael Torok, the Managing Director of JEC Capital Partners (together with their affiliates, the "Concerned Shareholder Group" or "we"), who collectively own approximately 3% of the outstanding shares of Atea Pharmaceuticals (NASDAQ:AVIR) ("Atea" or the "Company"), today issued the following open letter to the Company's Board of Directors: *** December 18, 2024 Board of Directors (the "Board") Atea Pharmaceuticals, Inc. 225 Franklin Street, Suite 2100 Boston, MA 02110 Directors, We own approximately 3% of the outstanding shares of Atea, collectively making us one of its largest shareholders. We are writing to express our concerns about the Company's share pr
BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting therapeutics for severe viral diseases, today announced the appointment of Nancy Gail Berry Agrawal, Ph.D., as Executive Vice President of Preclinical Development. Dr. Agrawal previously served as Vice President of Pharmacokinetics, Pharmacodynamics, and Drug Metabolism at Merck & Co., Inc. "We are delighted to welcome Nancy to the Atea team. Her broad scientific and managerial experience in both drug discovery and drug development spanning across multiple therapeutic areas at Merck, will enrich our scientific and c
BOSTON, June 15, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, today announced the appointment of Claudio Avila, MB, BS, Ph.D., as Senior Vice President of Medical Affairs. Dr. Avila previously served as Executive Director, U.S. Medical Strategy and Medical Affairs for COVID-19 at Gilead Sciences. "We are very pleased to welcome Claudio to the Atea team. Claudio's extensive expertise and experience in medical affairs with a focus on COVID-19, hepatitis and HIV as part of his overall interest in serious viral infectious diseases, will complement and s
BOSTON, May 20, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe viral infections, today announced the appointment of Jerome Adams, M.D., M.P.H., to its Board of Directors. Dr. Adams most recently served as Surgeon General of the United States and brings a wide range of experience spanning clinical practice, clinical research, public health, and government agency leadership. "We are honored to welcome Dr. Adams to our Board of Directors, as his unique experience as Surgeon General during the COVID-19 pandemic will undoubtedly help guide Atea as we continue to advance our ant
8-K - Atea Pharmaceuticals, Inc. (0001593899) (Filer)
SCHEDULE 13D - Atea Pharmaceuticals, Inc. (0001593899) (Subject)
144 - Atea Pharmaceuticals, Inc. (0001593899) (Subject)
Morgan Stanley upgraded Atea Pharmaceuticals from Underweight to Equal-Weight and set a new price target of $6.88 from $2.00 previously
JP Morgan downgraded Atea Pharmaceuticals from Neutral to Underweight
JP Morgan reiterated coverage of Atea Pharmaceuticals with a rating of Neutral and set a new price target of $8.00 from $10.00 previously
Topline SVR12 Results from Global Phase 2 Hepatitis C Virus (HCV) Study (N=275) Expected Q4'24 New Data Supportive of HCV Combination to be Presented at the American Association for the Study of Liver Diseases' (AASLD's) The Liver Meeting 2024 Pharmacokinetic Data for Bemnifosbuvir to be Presented at American College of Pharmacometrics Meeting Conference Call at 4:30 pm ET Today BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the third quarter ended Septem
BOSTON, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Thursday, November 7, 2024, at 4:30 p.m. ET to report financial results for the third quarter ended September 30, 2024, and to provide a business update. To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Pharmaceuticals website at ir
Full Enrollment Achieved in Global Phase 2 Hepatitis C Virus (HCV) Study; Complete SVR12 Results Expected 4Q'24 Bemnifosbuvir and Ruzasvir HCV Data Presented at EASL: Support Best-in-Class Potential with High Antiviral Potency, Low Risk of Drug Interaction, Short Treatment Duration and High Barrier to Resistance Results from COVID-19 Global Phase 3 SUNRISE-3 Trial Expected 2H'24 Conference Call at 4:30 pm ET Today BOSTON, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial resul
4/A - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)
SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)
SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)
4/A - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)